Ken Griffin Akebia Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $33,558 - $55,335	35,700 Added 38.89%	127,500 $168,000
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $37,238 - $70,579	-43,300 Reduced 32.05%	91,800 $93,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.24 $5,588 - $9,856	-4,400 Reduced 3.15%	135,100 $247,000
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $8,960 - $14,336	11,200 Added 8.73%	139,500 $172,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $16,443 - $34,776	18,900 Added 17.28%	128,300 $146,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $1.43 $17,646 - $49,478	34,600 Added 46.26%	109,400 $100,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $8,064 - $16,560	-14,400 Reduced 16.14%	74,800 $41,000
Q4 2022 Feb 14, 2023	BUY	$0.25 - $0.58 $3,525 - $8,177	14,100 Added 18.77%	89,200 $51,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $24,330 - $37,306	-81,100 Reduced 51.92%	75,100 $24,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $379M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.